Clinical trial
Phase 1b Double-Blind, Placebo-Controlled, Ascending Dose Trial: ORIN1001 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
NCT04643769 is registered in ClinicalTrials.gov with Orinove, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 1b Double-Blind, Placebo-Controlled, Ascending Dose Trial: ORIN1001 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
- Lead sponsor
- Orinove, Inc.
- Phase
- Phase 1
- Overall status
- Suspended
- Start date
- February 9, 2021
- Completion date
- December 30, 2025
- Enrollment
- 24 (estimated)
- Sites
- 11
Conditions
As the registry lists them; a condition with its own page is linked.